National Institute on Aging
31 Center Drive, MSC 2292
Building 31, Room 5C27
Bethesda
Maryland
20892
United States
Tel: 301-496-1752
Website: http://www.nia.nih.gov/
65 articles with National Institute on Aging
-
Praetego Inc Awarded $2.5M by the NIH National Institute of Aging to Advance Novel Drug Candidate Against Alzheimer's Disease
10/4/2022
Praetego Inc is pleased to announce a $2.5M STTR award from the National Institute of Aging.
-
Oligomerix Awarded $2.49M from NIH to Further Support Clinical Development of Tau-Targeting Alzheimer’s Disease Therapy Candidate OLX-07010
10/4/2022
Oligomerix, Inc. announced an award of $2.49 million from the National Institute on Aging of the National Institutes of Health to support clinical development of its lead program OLX-07010, an oral tau self-association small molecule inhibitor.
-
Cognition Therapeutics Awarded $2.14 Million in Supplemental Grant Funding from NIA to Support SEQUEL Clinical Trial
9/27/2022
Cognition Therapeutics, Inc. (Nasdaq: CGTX) announced today that the company has received a $2.14M grant award from the National Institute on Aging (NIA), a division of the National Institutes of Health (NIH), to support completion of the ongoing SEQUEL Study of CT1812 in adults with mild-to-moderate Alzheimer’s disease.
-
NIH researchers found that symptomatic herpes viruses were associated with neurological symptoms, but there was no evidence that herpes viruses are linked to Alzheimer’s disease.
-
Oligomerix Awarded $3.35M from NIH to Support Clinical Development of Tau-Targeting Alzheimer’s Disease Therapy
8/9/2022
Oligomerix, Inc., a privately held company pioneering the development of small molecule therapeutics targeting tau for rare neurodegenerative and Alzheimer’s diseases, today announced an award of $3.35 million from the National Institute on Aging of the National Institutes of Health to support clinical development of its lead program OLX-07010, an oral tau self-association small molecule inhibitor.
-
New research suggests that treatment with anti-amyloid-beta protofibril antibody lecanemab is estimated to slow the rate of disease progression in patients with Alzheimer’s Disease.
-
An investigation into the estrogen-brain link will be led by the Tulane Brain Institute’s multidisciplinary team, whose expertise spans across the pharmacology, physiology and molecular biology industries.
-
ALZ-801 is administered orally and works by blocking the formation of neurotoxic soluble amyloid oligomers that later lead to cognitive decline in Alzheimer's patients.
-
LifeBio Secures Second National Institute on Aging Grant; Research Will Use Artificial Intelligence as a Possible Diagnostic Tool for Alzheimer's
10/12/2021
LifeBio announced its second National Institute on Aging (NIA) Small Business Innovation Research (SBIR) grant of $448,462 to focus on the Alzheimer's disease population.
-
The NIH revealed that bumetanide, a drug typically used as a diuretic, maybe a potential treatment for those genetically at risk for Alzheimer's. Know more about it here.
-
Feinstein Institutes Receives $1.7M Grant to Study Behavior Change Science, Promote Exercise in Older Adults
9/9/2020
Only half of the adults in the United States get the exercise they need to help reduce and prevent chronic diseases.
-
“We are grateful to the NIA for their rigorous scientific review and funding support to advance ALZ-8801 for Alzheimer’s patients in need of an effective treatment,” said Martin Tolar, founder, president and chief executive officer of Alzheon.
-
In honor of Black History Month, BioSpace chose to highlight 10 African American leaders in the life sciences, individuals who have prominent roles in the life sciences and biopharmaceutical industry.
-
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
-
Researchers with the National Institute on Aging published research of a gene variant, APO3 Christchurch (APOE3ch), that appears to confer resistance to Alzheimer’s disease.
-
What is the best way to prevent or even reverse Alzheimer’s disease? That’s the question at the top of many researchers’ minds, especially given all of the recent large Phase 3 failures involving beta-amyloid targeting drugs, the most pursued target to date. This is troubling but not entirely sho...
-
Synthego Launches High-Throughput Induced Pluripotent Stem Cell Genome Engineering
10/22/2019
National Institutes of Health awards contract for CRISPR-based disease modeling in iPS cell lines associated with Alzheimer's, Stem cell pioneer Bill Skarnes joins advisory board
-
$53.4M Grant to Brown, Hebrew SeniorLife to Enable Massive Expansion of Alzheimer’s Research
9/10/2019
Federal grant from the National Institute on Aging will fund a collaborative research incubator to support trials across the nation aimed at improving care for people with dementia
-
Cognition Therapeutics Receives $3.3 Million NIA Grant to Conduct qEEG Study of Elayta™ with World-Leading Alzheimer’s Biomarker Experts
7/9/2019
Investigating Quantitative EEG as Biomarker of Patient Response to Treatment in Future Efficacy Studies
-
New IDSAF and NIA research grants will speed Alzheimer's microbe hunt, says Dr. Leslie Norins of Alzheimer's Germ Quest, Inc.
6/20/2019
The half-million dollars in Alzheimer's disease research grants recently announced by the Infectious Diseases Society of America Foundation, and the possibly millions of dollars of "high priority" grants now offered by the National Institute on Aging to study infectious agents in AD, are a "welcome affirmation" of the need to investigate more thoroughly the possible roles of germs in triggering AD, says Leslie Norins, MD, PhD, CEO of Alzheimer's Germ Quest, Inc.